Indications for Serotypes A and B Botulinum Toxins

April 16th, 2018 - Find-A-Code
Categories:   HCPCS Coding   Medicare   Drugs|Pharmaceuticals|FDA  

According to Novitas LCD L27476, the following indications apply:

1. Blepharospasm and strabismus

2. Spastic dystonia or focal dystonias to relieve pain, to assist posturing and walking, to increase range of motion, to assist in the outcome of physical therapy, and/or to reduce spasm thus allowing adequate perineal hygiene.

3. Spasmodic dysphonia

4. Achalasia and cardiospasm when at least one of the following conditions is met:

  • Patient has failed conventional therapy or has a contraindication to such therapy
  • Patient is at high risk of complications from pneumatic dilation or surgical myotomy
  • Prior myotomy or dilation has failed
  • Prior dilation-induced esophageal perforation
  • Patient has an epiphrenic diverticulum or hiatal hernia

5. Severe primary focal hyperhidrosis in patients who are not adequately managed with topical agents or ionotophoresis (or have a contraindication to such treatment), and who manifest all of the following indications:

  • Severe sweating beyond physiological needs
  • Focal, visible, severe sweating of at least 6 months duration without apparent cause with at least 2 of the following characteristics:

    – Bilateral and relatively symmetric
    – Significant impairment in daily activities
    – Age of onset less than 25 years
    – Positive family history
    – Cessation of focal sweating during sleep

6. Disability from sialorrhea due to conditions such as motor neuron disease or Parkinson’s disease in those patients who have failed to respond to a reasonable trial of traditional therapies (i.e., anticholinergics, speech therapy, surgical therapy), or who have a contraindication to traditional therapy.

7. OnabotulinumtoxinA, serotype A botulinum toxin, can be used to treat urinary incontinence due to neurogenic bladder or bladder over-activity. This treatment will be considered reasonable and necessary if used only after documented failure of medical therapy.

8. OnabotulinumtoxinA, serotype A botulinum toxin is considered reasonable and necessary for prophlaxis/treatment of headaches in adult patients with chronic intractable migraine more than 15 days/month, with headache lasting 4 hours a day or longer.

The determination regarding whether serotypes A or B botulinum toxin is the most appropriate course of treatment should be based on the physician’s judgment, clinical experience, and the patient’s individual history. If the clinical use of the drug is not an FDA approved use for the specific botulinum toxin product, peer-reviewed medical literature supporting that use should be kept on file and the claim should be submitted with a KX modifier. The KX modifier should not be used for diagnoses that are specifically noted as not reasonable and necessary in this drug policy. See the article: “Approved Drugs and Biologicals; Includes Cancer Chemotherapeutic Agents” (A47797) for further details.

Electrical Stimulation for chemodenervation or electromyography procedure(s) may be medically necessary when the proper injection site(s) are difficult to determine.


Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.

Latest articles:  (any category)

Artificial Intelligence in Healthcare - A Medical Coder's Perspective
December 26th, 2023 - Aimee Wilcox
We constantly hear how AI is creeping into every aspect of healthcare but what does that mean for medical coders and how can we better understand the language used in the codeset? Will AI take my place or will I learn with it and become an integral part of the process that uses AI to enhance my abilities? 
Specialization: Your Advantage as a Medical Coding Contractor
December 22nd, 2023 - Find-A-Code
Medical coding contractors offer a valuable service to healthcare providers who would rather outsource coding and billing rather than handling things in-house. Some contractors are better than others, but there is one thing they all have in common: the need to present some sort of value proposition in order to land new clients. As a contractor, your value proposition is the advantage you offer. And that advantage is specialization.
ICD-10-CM Coding of Chronic Obstructive Pulmonary Disease (COPD)
December 19th, 2023 - Aimee Wilcox
Chronic respiratory disease is on the top 10 chronic disease list published by the National Institutes of Health (NIH). Although it is a chronic condition, it may be stable for some time and then suddenly become exacerbated and even impacted by another acute respiratory illness, such as bronchitis, RSV, or COVID-19. Understanding the nuances associated with the condition and how to properly assign ICD-10-CM codes is beneficial.
Changes to COVID-19 Vaccines Strike Again
December 12th, 2023 - Aimee Wilcox
According to the FDA, CDC, and other alphabet soup entities, the old COVID-19 vaccines are no longer able to treat the variants experienced today so new vaccines have been given the emergency use authorization to take the place of the old vaccines. No sooner was the updated 2024 CPT codebook published when 50 of the codes in it were deleted, some of which were being newly added for 2024.
Updated ICD-10-CM Codes for Appendicitis
November 14th, 2023 - Aimee Wilcox
With approximately 250,000 cases of acute appendicitis diagnosed annually in the United States, coding updates were made to ensure high-specificity coding could be achieved when reporting these diagnoses. While appendicitis almost equally affects both men and women, the type of appendicitis varies, as dose the risk of infection, sepsis, and perforation.
COVID Vaccine Coding Changes as of November 1, 2023
October 26th, 2023 - Wyn Staheli
COVID vaccine changes due to the end of the PHE as of November 1, 2023 are addressed in this article.
Medicare Guidance Changes for E/M Services
October 11th, 2023 - Wyn Staheli
2023 brought quite a few changes to Evaluation and management (E/M) services. The significant revisions as noted in the CPT codebook were welcome changes to bring other E/M services more in line with the changes that took place with Office or Other Outpatient Services a few years ago. As part of CMS’ Medicare Learning Network, the “Evaluation and Management Services Guide” publication was finally updated as of August 2023 to include the changes that took place in 2023. If you take a look at the new publication (see references below),....

Home About Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2024 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association